Skip to main content

Press releases | August 28, 2017

Fried Frank acted as counsel to Bank of America Merrill Lynch and Lazard, as financial advisors to Gilead Sciences in its definitive agreement to acquire Kite Pharma for US$180.00 per share or approximately US$11.9 billion. The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers. The transaction is expected to close in the fourth quarter of 2017.   

The Fried Frank team was led by corporate partner Philip Richter and included corporate associate Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.